|
|
 |
| Research Articles |
|
| Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. |
Oren Zimhony, Jeffery S. Cox, John T. Welch, Catherine Vilcheze, William R. Jacobs.
doi:10.1038/79558
|
| Nature Medicine 2000 Sep;6(9):1043—1047. |
|
|
Abstract |
Full Text |
PDF |
|
 |
|
| Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. |
Sharma V, Sharma S, Hoener zu Bentrup K, McKinney JD, Russell DG, Jacobs WR Jr, Sacchettini JC
doi:10.1038/77964
|
| Nature Structural Biology 2000 Aug;7(8):663—668. |
|
|
Abstract |
Full Text |
PDF |
|
|
|
| Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterialdrugs and vaccines. |
Ronning DR, Klabunde T, Besra GS, Vissa VD, Belisle JT, Sacchettini, JC.
doi:10.1038/72413
|
| Nature Structural Biology 2000 Feb;7(2):141—146. |
|
|
Abstract |
Full Text |
PDF |
|
|
|
| Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. |
McKinney, J.D. et al.
doi:10.1038/35021074
|
| Nature 2000 ;406(6797):735—738. |
|
|
Abstract |
Full Text |
PDF |
|
|
|
| CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. |
Moody, D. B.
doi:10.1038/35009119
|
| Nature 2000 ;404(6780):884—888. |
|
|
Abstract |
Full Text |
PDF |
|
|
|
